Lv Suqin, Li Aihua, Wu Haijuan, Wang Xiaoli
Outpatient Pharmacy, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
Department of Pharmacy, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China.
Oncol Lett. 2019 Mar;17(3):3411-3417. doi: 10.3892/ol.2019.9966. Epub 2019 Jan 24.
Efficacy and toxic and side effects of pirarubicin combined with cytarabine and mitoxantrone combined with cytarabine on the treatment of initially treated acute myeloid leukemia (AML) were compared. A retrospective analysis was performed on the medical records of 76 AML patients who were initially treated in Weifang People's Hospital. Among them, 36 patients (observation group) were treated with pirarubicin combined with cytarabine, and 40 patients (control group) were treated with mitoxantrone combined with cytarabine. The efficacy and toxic and side effects on patients in the two groups were observed. There was no statistically significant difference in the complete response (CR) rate, partial response (PR) rate and overall response (OR) rate of patients between the two groups (P>0.05). Patients in the observation group had significantly lower incidence of cardiotoxicity and alopecia than those in the control group (P<0.05). Patients in the observation group had lower incidence of bone marrow depression (BMD) at grade IV than those in the control group (P<0.05). The median progression-free survival time of patients was 14.5 months in the observation group and 18 months in the control group. The progression-free survival rate of patients was 36.11% in the observation group and 40.00% in the control group, with no difference between the two groups (P>0.05). The median survival time of patients was 22.5 months in the observation group and 24.5 months in the control group. The overall survival (OS) rate of patients was 44.44% in the observation group and 47.50% in the control group, with no difference between the two groups (P>0.05). Both pirarubicin combined with cytarabine and mitoxantrone combined with cytarabine have satisfactory efficacy on initially treated AML. Compared to the latter, the former has lower toxic and side effects.
比较吡柔比星联合阿糖胞苷与米托蒽醌联合阿糖胞苷治疗初治急性髓系白血病（AML）的疗效及毒副作用。对在潍坊市人民医院接受初治的76例AML患者的病历进行回顾性分析。其中，36例患者（观察组）接受吡柔比星联合阿糖胞苷治疗，40例患者（对照组）接受米托蒽醌联合阿糖胞苷治疗。观察两组患者的疗效及毒副作用。两组患者的完全缓解（CR）率、部分缓解（PR）率和总缓解（OR）率比较，差异无统计学意义（P>0.05）。观察组患者的心脏毒性和脱发发生率明显低于对照组（P<0.05）。观察组患者Ⅳ度骨髓抑制（BMD）发生率低于对照组（P<0.05）。观察组患者的无进展生存时间中位数为14.5个月，对照组为18个月。观察组患者的无进展生存率为36.11%，对照组为40.00%，两组差异无统计学意义（P>0.05）。观察组患者的生存时间中位数为22.5个月，对照组为24.5个月。观察组患者的总生存（OS）率为44.44%，对照组为47.50%，两组差异无统计学意义（P>0.05）。吡柔比星联合阿糖胞苷与米托蒽醌联合阿糖胞苷治疗初治AML均有满意疗效。与后者相比，前者毒副作用更低。
